Request Deal Involvement

LENZ Therapeutics completed the merger with Graphite Bio in a $225m deal.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Leerink Partners

financial advisors

Leerink Partners

Goodwin Procter

legal advisors

Goodwin Procter

Piper Sandler

financial advisors

Piper Sandler

William Blair & Co

financial advisors

William Blair & Co

Latham & Watkins

legal advisors to financial advisors

Latham & Watkins

Bank of America

financial advisors

Bank of America

Citigroup

financial advisors

Citigroup

Wilson Sonsini Goodrich & Rosati

legal advisors

Wilson Sonsini Goodrich & Rosati

Precision AQ

pr advisors

Precision AQ

or

Principals

ALPHA WAVE VENTURES

vendor

ALPHA WAVE VENTURES

SECTORAL ASSET MANAGEMENT

vendor

SECTORAL ASSET MANAGEMENT

GRAPHITE BIO

target

GRAPHITE BIO

LENZ THERAPEUTICS

bidder

LENZ THERAPEUTICS

VERSANT VENTURES

vendor

VERSANT VENTURES

RA CAPITAL MANAGEMENT

vendor

RA CAPITAL MANAGEMENT

POINT72 VENTURES

vendor

POINT72 VENTURES

SAMSARA BIOCAPITAL

vendor

SAMSARA BIOCAPITAL

RTW INVESTMENTS

vendor

RTW INVESTMENTS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - LENZ Therapeutics completed the merger with Graphite Bio in a $225m deal.